Reata Pharmaceuticals Inc (RETA.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2015||Chairman of the Board, President, Chief Executive Officer|
|47||2015||Chief Financial Officer and Vice President, Strategy|
|38||Chief Medical Officer and Vice President, Product Development|
|47||Vice President, Chief Development Officer|
|69||2015||Vice President, Chief Legal Officer|
- BRIEF-Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock
- BRIEF-Reata Pharmaceuticals Q3 loss per share $0.50
- BRIEF-Reata Pharmaceuticals enters first amendment to loan and security agreement
- BRIEF-Reata provides update on Bardoxolone Methyl from American Society of Nephrology Kidney Week Meeting
- BRIEF-Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone